STOCK TITAN

Jaguar Health Inc - JAGX STOCK NEWS

Welcome to our dedicated news page for Jaguar Health (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jaguar Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jaguar Health's position in the market.

Rhea-AI Summary
Jaguar Health, Inc. (JAGX) provides an update on its Nasdaq listing status, facing potential delisting due to low stock prices. The company has requested a hearing, and the stock will continue trading pending the appeal decision. Jaguar is working on data analysis for its Phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea prevention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none
-
Rhea-AI Summary
Jaguar Health, Inc. (JAGX) announces agreement with FDA for a clinical field study of Canalevia-CA1, a prescription drug for chemotherapy-induced diarrhea (CID) in dogs. The drug received conditional approval in December 2021 and is the first of its kind. The study aims for full approval by collecting evidence of effectiveness. Canalevia-CA1 helps dogs undergoing chemotherapy by improving comfort and quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
clinical trial
-
Rhea-AI Summary
Jaguar Health, Inc. (JAGX) donates plant-based drug Mytesi to Direct Relief, a humanitarian aid organization, to expand access to healthcare globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
Rhea-AI Summary
Jaguar Health (JAGX) submits an Orphan Drug Designation application to the FDA for crofelemer, a plant-based drug, for the treatment of cholera-related diarrhea. The company aims to address rare diseases with crofelemer and expects results from proof-of-concept studies for microvillus inclusion disease (MVID) and short bowel syndrome (SBS) by 2025. Crofelemer has been granted ODD for MVID and SBS by the FDA and EMA. The potential market exclusivity and development incentives for crofelemer are highlighted, targeting a significant global health issue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.95%
Tags
clinical trial
-
Rhea-AI Summary
Jaguar Health, Inc. announced a preclinical study by Magdalena Biosciences, Inc. indicating psychoactive activity in a plant extract for mental health conditions such as ADHD, depression, and anxiety. The study shows potential for a next-generation psychoactive prescription drug candidate for treatment of mental health disorders. Magdalena aims to submit an Investigational New Drug (IND) application to the FDA in 2024 and enter the clinic with at least one botanical drug candidate. This comes as the World Health Organization estimates mental disorders to affect one in four people worldwide, with costs associated with lost productivity expected to reach $16 trillion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
-
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) announced that Lisa Conte, the company's founder, president, and CEO, will present at The Microcap Conference in Atlantic City, New Jersey, on January 31, 2024, and participate in a fireside chat and one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference on February 1, 2024. The webcasted fireside chat will be available for replay, and management will be participating in virtual one-on-one meetings throughout the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
conferences
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) announced the publication of a dog study evaluating the effects of crofelemer in providing symptomatic relief of diarrhea associated with a cancer therapy drug. The study demonstrates the potential for crofelemer to reduce the severity and incidence of diarrhea in patients undergoing cancer therapy, addressing a growing unmet medical need. The study results highlight the scientific rationale for the use of crofelemer in humans, offering hope for the treatment of chemotherapy-induced diarrhea (CTD).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.65%
Tags
none
-
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) granted 7,500 restricted stock units (RSUs) to a new employee, vesting equally over three years. The RSUs were granted as an inducement material to the employee's acceptance of employment and approved by the Compensation Committee of Jaguar's Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Napo Pharmaceuticals (Jaguar Health) announced the issuance of a new U.S. patent for crofelemer, their novel plant-based prescription drug, for the treatment of congenital diarrheal disorders (CDDs). Jaguar is supporting clinical studies for rare disease indications, including microvillus inclusion disease (MVID) and short bowel syndrome (SBS), with results expected in 2024. Crofelemer has been granted Orphan Drug Designation (ODD) by the FDA and the European Medicines Agency for both MVID and SBS with intestinal failure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.63%
Tags
none
Rhea-AI Summary
Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) company, announced the completion of Stage II of the OnTarget trial for prophylaxis of diarrhea in cancer patients. Comprehensive results are expected in Q1 2024. The company's regulatory pathway for FDA approval remains on track. The trial addresses the unmet need for new therapies for cancer therapy-related diarrhea, with the majority of subjects choosing to continue to Stage II.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.94%
Tags
clinical trial
Jaguar Health Inc

Nasdaq:JAGX

JAGX Rankings

JAGX Stock Data

4.49M
40.68M
15.72%
2.43%
7.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About JAGX

jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/